*Sponsored by Nutriband Inc.
Market Crux Announces Early Coverage On ( NTRB) Starting Today—Wednesday, July 2, 2025
Here's What We Can Tell You—Right Now…
The Last Two Times We Covered (NTRB) It Moved Approximately 31% And 42% In Short Windows.
Just Yesterday (NTRB) Was Added To Several Russell Indexes Increasing Its Visibility Among Institutional Radars.
With Under 4.5M Shares Listed In The Float (NTRB) Could See Significant Swing Potential If Demand Begins To Shift.
Noble Capital Markets Recently Raised Their Target On (NTRB) To $15, Which Could Suggest Over 90% Upside Potential From Current Range.
Take A Look At (NTRB) This Morning While It's Still Quiet…
July 2, 2025 Dear Reader, This morning's announcement from (NTRB) has our attention now. FDA progress is moving into focus as (NTRB) advances toward filing for approval of its AVERSA™ Fen-tan-yl product, following the recent completion of its manufacturing scale-up with Kindeva. In alignment with this milestone, the company has announced a 25% preferred stock dividend for shareholders of record on July 25, 2025, with the issuance scheduled for August 5. Shareholders will receive one preferred share for every four common shares held. These preferred shares are designed to convert into common shares upon FDA approval, or, if unconverted, will qualify for annual cash dividends from company profits at the Board's discretion. CEO Gareth Sheridan noted this step reflects the company's focus on building shareholder value while advancing toward commercialization in the transdermal delivery space. Now, if you missed my email from earlier, keep reading to get up to speed on (NTRB) while it's still early. After last week's Thursday-Friday profile moved approximately 94% in under 24 hours, our focus this morning, Wednesday, July 2, 2025, is now on Nutriband Inc. (NASDAQ: NTRB).
Companies flying under the radar can often stay overlooked until key developments bring them into the spotlight. When the right potential catalysts start to come into view, attention can move quickly—practically overnight in some cases. That's exactly what's unfolding here. (NTRB) has moved into focus following a series of updates that could signal the potential for continued momentum.
But keep in mind, (NTRB) has a very limited float with less than 4.5 Mln shares listed as available to the public. A few weeks ago, we highlighted (NTRB) as it went from a $6.50 close on Friday, May 30, to $8.55 by Monday, June 2—an approximate 31% move in just days. Before that, we covered it as it went from $5.68 to $8.11 within 24 hours, for an approximate 42% move. Recently, Robert LeBoyer, Senior Vice President and Equity Research Analyst at Noble Capital Markets, raised his target on (NTRB) to $15, which suggests over 90% upside potential from yesterday's $7.86 open. 
Just yesterday, (NTRB) was officially added to several Russell indexes, including growth-focused benchmarks, as part of the 2025 reconstitution. This inclusion could have the potential to draw in the attention of institutional funds and index strategies that track these widely followed benchmarks, expanding market visibility at a pivotal point for the company. On the technical side, Barchart highlighted (NTRB) with 13 out of 13 bullish signals across short-, medium-, and long-term indicators, underscoring the momentum potential in its trend. A New Phase Begins
This is a company with a clear, focused mission: improving the safety of transdermal delivery. Its lead product, AVERSA™ Fen-tan-yl, isn't just another patch—it's designed as an abuse-deterrent transdermal system that could reshape how these therapies are delivered to those who need them while reducing the risks of misuse. In June, (NTRB) and its partner Kindeva announced they had completed the commercial manufacturing process scale-up for AVERSA Fen-tan-yl, marking a pivotal step forward. This move means the company is preparing to file its Investigational (IND) application with the FDA for clinical testing—a necessary gateway to commercial readiness 
Protected By Patents
(NTRB)'s AVERSA™ technology is protected by a broad patent portfolio in 46 countries, including the United States, Europe, Japan, Korea, and China. This coverage strengthens the foundation for its transdermal abuse-deterrent platform, which can be applied to a range of dr-ugs with potential misuse risks, including opi-oids and stimulants. This innovation matters, particularly in a landscape where transdermal fen-tan-yl remains a necessary treatment, yet carries a high risk of misuse. AVERSA aims to address this gap without restricting patient access. A Behind-The-Scenes Moment
Recently, Gareth Sheridan, CEO of Nutriband, emphasized the significance of completing the manufacturing scale-up, calling it "an important step toward the development of a commercially viable product and eventual NDA filing." He underscored how the milestone demonstrates the compatibility of AVERSA technology with established manufacturing processes, providing a clear path toward clinical testing and future commercial rollout. For (NTRB), only a single Phase 1 study is required under the FDA's 505(b)(2) pathway, and the trial is designed specifically to demonstrate that the patch is less preferable for misuse compared to conventional fen-tan-yl patches—an approach considered a low-risk step toward approval. Recent Developments:
- June 3, 2025: The USPTO issued a U.S. patent further expanding coverage for Nutriband's AVERSA technology.
- June 18, 2025: Nutriband and Kindeva completed the commercial manufacturing scale-up for AVERSA Fen-tan-yl, preparing for IND filing and clinical testing.
- The technology holds the potential to become the first abuse-deterrent pain patch on the market, with peak annual U.S. sales estimates ranging from $80M to $200M, according to company statements.
Why (NTRB) Is On Our Radar
This is a pivotal moment for (NTRB). It has moved from a concept to a tangible pathway toward market readiness, backed by a partner with global manufacturing capabilities and a clear regulatory roadmap. The addressable need for safer transdermal therapies remains significant, and the technical and regulatory progress seen over the past weeks positions (NTRB) in a stronger light than many might realize. If you want to follow a company aligned with a clear mission, credible technology, and a tangible timeline for its next steps, (NTRB) deserves a place on your screen right now. Now's the time to keep an eye on (NTRB) as this story continues to unfold. 7 Reasons Why (NTRB) Just Hit Our Radar This Morning
—Wednesday, July 2, 2025
1. Recent Momentum: during our last two coverage announcements, (NTRB) has moved approximately 31% and 42% in short windows, reflecting past momentum during key moments. 2. New Index Addition: just yesterday, (NTRB) was added to several Russell indexes, which has the potential to increase its visibility among institutional radars. 3. Analyst Raise Target: Noble Capital Markets has raised their target on (NTRB) to $15, citing updated FY2027 EPS projections and market positioning.
4. Limited Float: with under 4.5M shares listed in the float, (NTRB) could witness the potential for significant swings if demand begins to suddenly change. 5. Strong Technical Signals: Barchart recently highlighted (NTRB) with 13 out of 13 bullish signals across short-, medium-, and long-term indicators, underscoring consistent momentum in its trend. 6. Patent-Backed Platform: with coverage in 46 countries, (NTRB) holds broad protection for its AVERSA™ transdermal technology. 7. FDA Milestone On Deck: in June, (NTRB) and partner Kindeva completed scale-up for AVERSA Fen-tan-yl, preparing for FDA filing. 
Try To Get (NTRB) On Your Screen This Morning—While It's Still Quiet…
With Noble Capital Markets setting a $15 target, a low float under 4.5M shares, and fresh addition to several Russell indexes just yesterday, (NTRB) could be positioned to catch more eyes.
The last two times we highlighted (NTRB), it moved approximately 31% and 42% in short windows, a reminder of how quickly attention can shift when momentum builds. Now, with Barchart showing 13 out of 13 bullish signals, the technical backdrop is hard to overlook. Backed by patents in 46 countries and a completed manufacturing scale-up for AVERSA™ Fen-tan-yl, (NTRB) is preparing for its next phase. (NTRB) has officially landed back on our radar. We have all eyes on (NTRB) this morning. The company has announced a 25% preferred stock dividend for shareholders of record on July 25, 2025, with the issuance scheduled for August 5. Take a look while it's still quiet. My next update could be out within a few minutes—please keep an eye out for it. Sincerely, Gary Silver
Managing Editor, Market Crux
| 
No comments:
Post a Comment